An online survey of Australian physicians reported practice with the off-label use of nebulised frusemide

Publisher:
BioMed Central
Publication Type:
Journal Article
Citation:
BMC Palliative Care, 2012, 11 (6)
Issue Date:
2012-04-30
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2011003799OK.pdf197.81 kB
Adobe PDF
Background: Off-label prescribing is common in palliative care. Despite inconsistent reports of the benefit of nebulised frusemide for breathlessness, its use continues to be reported. An online survey was emailed to 249 members of the Australian and New Zealand Society of Palliative Medicine to estimate the use of nebulised frusemide for breathlessness by Australian physicians involved in palliative care in the previous 12 months. There were 52/249 (21%) respondents to the survey. The majority (44/52; 85%) had not prescribed nebulised frusemide in the previous 12 months. The most common (18/44; 43%) reason for not prescribing nebulised frusemide was a belief that there was not enough evidence to support its use. Whilst only a few respondents (8/52; 15%) reported having used nebulised frusemide, all that had used it thought there was at least some benefit in relieving breathlessness. This report adds to the series of case studies reporting some benefit from nebulised frusemide in relieving breathlessnes.
Please use this identifier to cite or link to this item: